Vito De Gennaro Colonna

Vito De Gennaro Colonna

Auto-generated profile, based on publicly available information

Vito De Gennaro Colonna

Obesity and Work Centre, Occupational Medicine Unit, Clinica del Lavoro L. Devoto, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2002 in European Journal of Pharmacology
Verified
Journal Article
Closed access
VCVito De Gennaro Colonna
Vito De Gennaro Colonna
GRGiuseppe Rossoni
Giuseppe Rossoni
ARAntonello Emilio Rigamonti
Antonello Emilio Rigamonti
SBSara Bonomo
Sara Bonomo
BMBarbara Manfredi
Barbara Manfredi
EMEugenio E Muller
Eugenio E Muller

1 June 2005 in European Journal of Pharmacology
Verified
Journal Article
Closed access
VCVito De Gennaro Colonna
Vito De Gennaro Colonna
ARAntonello Emilio Rigamonti
Antonello Emilio Rigamonti
SFSimona Fioretti
Simona Fioretti
SBSara Bonomo
Sara Bonomo
BMBarbara Manfredi
Barbara Manfredi
GRGiuseppe Rossoni
Giuseppe Rossoni

1 April 2009
Verified
Journal Article
Closed access
VCVito De Gennaro Colonna
Vito De Gennaro Colonna
MBMauro Bianchi
Mauro Bianchi
VPValerio Pascale
Valerio Pascale
PFPaolo Ferrario
Paolo Ferrario
FMFranca Morelli
Franca Morelli
MTMaurizio Turiel
Maurizio Turiel

Verified
Journal Article
Open access
PDF file
SSsimona wilde giovanna servida
simona wilde giovanna servida
EPElena Panzeri
Elena Panzeri
LTLaura Tomaino
Laura Tomaino
GMGiovanni Marfia
Giovanni Marfia
EGEmanuele Garzia
Emanuele Garzia
LVLuisella Vigna
Luisella Vigna
The hypoglycemic properties of curcumin supplements in therapeutic doses are well-known and may represent a useful tool for the treatment of chronic diseases such as metabolic syndrome, insulin resistance and type 2 diabetes. The poor bioavailability of curcumin can be improved with the concomitant administration of piperine, with no severe adverse effects on glycemia reported so far in the literature. In this article, we further discuss a previously reported case of a helicopter pilot, affected by grade I obesity who, under curcumin and piperine treatment, experienced a transient loss of consciousness (TLOC), during a low-altitude flight. This episode led to a diagnosis of insulinoma, previously asymptomatic. We hypothesized that the combined effects of curcumin and piperine might have caused a severe hypoglycemic episode and subsequent TLOC. Therefore, further studies should be conducted to evaluate the safety of curcumin and piperine supplementation in subjects with impaired glucose metabolism and insulin secretion.

1 January 2013 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
VPValerio Pascale
Valerio Pascale
WPWalter Pascale
Walter Pascale
VLVito Lavanga
Vito Lavanga
Valerio SansoneValerio Sansone
Valerio Sansone
PFPaolo Ferrario
Paolo Ferrario
VCVito De Gennaro Colonna
Vito De Gennaro Colonna
The aim of this study was to investigate the involvement of the nitric oxide (NO) pathway in osteoarthritis (OA). The study groups consisted of 32 patients with knee OA and 31 healthy controls. In peripheral venous blood samples (from the OA patients and the controls) and in synovial fluid samples (from the OA patients), the concentrations of L-arginine (ARN), asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) were evaluated. In plasma samples, thiobarbituric acid reactive substances (TBARS) were also measured. Plasma ARN concentrations were lower in the OA patients than in controls (53.55 ± 16.37 vs. 70.20 ± 25.68 µmol/l) (P<0.05), while plasma ADMA concentrations were similar. Accordingly, the ARN/ADMA ratio was lower in the OA patients than in the control group (80.85 ± 29.58 vs. 110.51 ± 30.48, P<0.05). Plasma SDMA and TBARS concentrations were higher in the OA patients than in controls (0.69 ± 0.15 vs. 0.60 ± 0.10 µmol/l, P<0.05 and 1.21 ± 0.29 vs. 0.55 ± 0.12, respectively) (P<0.001). In the OA patients, ADMA concentrations were significantly higher in the synovial fluid than in plasma (0.75 ± 0.09 vs. 0.69 ± 0.14 µmol/l, P<0.05), as were ARN concentrations (76.96 ± 16.73 vs. 53.55 ± 16.73 µmol/l) (P<0.00001). Conclusions These results indicate a poor availability of NO in the synovial fluid of the OA patients, which may contribute to the progression of OA. The decreased ARN/ADMA ratio and the increased SDMA and TBARS in the plasma of the OA patients suggest an impairment of endothelial function in these subjects.

28 February 2007 in European Journal of Pharmacology
Verified
Journal Article
Closed access
VCVito De Gennaro Colonna
Vito De Gennaro Colonna
SBSara Bonomo
Sara Bonomo
PFPaolo Ferrario
Paolo Ferrario
MBMauro Bianchi
Mauro Bianchi
MBMarco Berti
Marco Berti
GRGiuseppe Rossoni
Giuseppe Rossoni